MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Pulmonology, Respiratory
Aradigm Corporation (OTCBB:ARDM)
Organization & Developments: Aradigm
Parents
*Architects: Infectious Disease _ Bacteriology_Antibiotics
Aradigm Corporation (OTCBB:ARDM)
Children
2015: The company is developing Pulmaquin in collaboration with Grifols, which has funded $65 million of development expenses as part of the agreement and owns approximately 35% of the company.
2017: Aradigm: How Does It Look A Month Before The Critical AdComm? - Aradigm Corp. (NASDAQ:ARDM)
2017: Aradigm: Huge Upside On Linhaliq Approval - Aradigm Corp. (NASDAQ:ARDM)
2018: Aradigm crashes after FDA panel votes down antibiotic
2018: Aradigm plummets 37% ahead of Ad Com review of Linhaliq - Aradigm Corp. (NASDAQ:ARDM)
2018: EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Aradigm Corporation – ARDM
2018: FDA panel rejects Aradigm/Grifols’ inhaled antibiotic
2019: Throwing in the towel, troubled antibiotic maker Aradigm files for Chapter 11 – Endpoints News
DEVELOPS DRUGS DELIVERED BY INHALATION FOR THE TREATMENT AND PREVENTION OF SEVERE RESPIRATORY DISEASES
Propriety inhaled antibiotic called Pulmaquin that is in development for the treatment of non-cystic fibrosis bronchiectasis.
Jumps
*Key People: Aradigm
Finance & Acquisitions: Aradigm